大规模青蒿素-哌喹联合或不联合伯氨喹群体给药显著降低非洲高流行区疟疾
在科摩罗昂儒昂岛,对2个区(97164人)给予青蒿素-哌喹联合低剂量伯氨喹、5个区(224471人)单用青蒿素-哌喹,每月1轮共3轮,覆盖率85%至93%。2012年和2013年4月至9月,联合组疟疾住院率从每10万人310.8降至2.06,单药组从412.1降至2.60,两方案耐受良好且未发现PfK13 Kelch螺旋桨突变选择。
要点
- 3轮每月青蒿素-哌喹联合或不联合伯氨喹群体给药覆盖率85%至93%。
- 联合组疟疾住院率从310.8降至2.06/10万人,单药组从412.1降至2.60。
- 两方案耐受良好,无严重不良事件,未发现PfK13 Kelch螺旋桨突变选择。
核心结论
- 3轮每月青蒿素-哌喹联合或不联合低剂量伯氨喹均实现疟疾病例大幅下降,提示在昂儒昂岛这类流行病学 settings 中不联合伯氨喹的群体给药可能高度成功。
- 主要挑战是维持和扩大群体给药带来的疟疾下降的公共卫生收益。
研究设计与样本
- 在科摩罗联盟昂儒昂岛全岛,对2个区(人口97164)给予青蒿素-哌喹联合低剂量伯氨喹,对5个区(人口224471)单用青蒿素-哌喹,每月1轮共3轮。
- 评估恶性疟原虫疟疾发生率、死亡率、寄生虫血症、不良事件和PfK13 Kelch螺旋桨基因多态性。
主要发现
- 2012年和2013年4月至9月,联合组平均每月疟疾住院率从每10万人310.8降至2.06(比值2.06/310.8=0.66%;95%CI:0.02%,3.62%;P=.00007)。
- 单药组平均每月疟疾住院率从每10万人412.1降至2.60(比值0.63%;95%CI:0.11%,1.93%;P<.00001)。
- 联合组有效率为0.9908(95%CI:0.9053,0.9991),单药组有效率为0.9913(95%CI:0.9657,0.9978)。
- 两方案耐受良好,无严重不良事件;群体给药后分析52份疟疾样本,未发现PfK13 Kelch螺旋桨突变选择的证据。
临床怎么用
- 原文结论提示,在昂儒昂岛这类流行病学 settings 中,不联合伯氨喹的群体给药可能高度成功。
- 原文指出主要挑战是维持和扩大群体给药带来的疟疾下降的公共卫生收益。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Mass drug administration (MDA), with or without low-dose primaquine (PMQLD), is being considered for malaria elimination programs. The potential of PMQLD to block malaria transmission by mosquitoes must be balanced against liabilities of its use. METHODS: Artemisinin-piperaquine (AP), with or without PMQLD, was administered in 3 monthly rounds across Anjouan Island, Union of Comoros. Plasmodium falciparum malaria rates, mortality, parasitemias, adverse events, and PfK13 Kelch-propeller gene polymorphisms were evaluated. RESULTS: Coverage of 85 to 93% of the Anjouan population was achieved with AP plus PMQLD (AP+PMQLD) in 2 districts (population 97164) and with AP alone in 5 districts (224471). Between the months of April-September in both 2012 and 2013, average monthly malaria hospital rates per 100000 people fell from 310.8 to 2.06 in the AP+PMQLD population (ratio 2.06/310.8 = 0.66%; 95% CI: 0.02%, 3.62%; P = .00007) and from 412.1 to 2.60 in the AP population (ratio 0.63%; 95% CI: 0.11%, 1.93%; P < .00001). Effectiveness of AP+PMQLD was 0.9908 (95% CI: 0.9053, 0.9991), while effectiveness of AP alone was 0.9913 (95% CI: 0.9657, 0.9978). Both regimens were well tolerated, without severe adverse events. Analysis of 52 malaria samples after MDA showed no evidence for selection of PfK13 Kelch-propeller mutations. CONCLUSIONS: Steep reductions of malaria cases were achieved by 3 monthly rounds of either AP+PMQLD or AP alone, suggesting potential for highly successful MDA without PMQLD in epidemiological settings such as those on Anjouan. A major challenge is to sustain and expand the public health benefits of malaria reductions by MDA.
引用
- Deng C, Huang B, Wang Q, et al. Large-scale Artemisinin-Piperaquine Mass Drug Administration With or Without Primaquine Dramatically Reduces Malaria in a Highly Endemic Region of Africa. Clin Infect Dis. 2018. PMID: 29846536. doi:10.1093/cid/ciy364
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。